Twist Bioscience (NASDAQ:TWST) Releases Earnings Results, Beats Expectations By $0.11 EPS

Twist Bioscience (NASDAQ:TWST) announced its earnings results on Friday. The company reported ($0.81) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.92) by $0.11, MarketWatch Earnings reports. Twist Bioscience had a negative return on equity of 29.09% and a negative net margin of 88.97%. The business had revenue of $66.95 million for the quarter, compared to analyst estimates of $63.35 million. During the same quarter last year, the firm earned ($0.91) EPS. Twist Bioscience’s revenue for the quarter was up 16.8% compared to the same quarter last year.

Twist Bioscience Price Performance

Shares of NASDAQ TWST opened at $24.01 on Friday. The stock has a market capitalization of $1.38 billion, a PE ratio of -6.49 and a beta of 1.32. The business has a fifty day moving average price of $18.69 and a two-hundred day moving average price of $19.07. Twist Bioscience has a fifty-two week low of $11.46 and a fifty-two week high of $31.51.

Wall Street Analysts Forecast Growth

TWST has been the topic of a number of recent research reports. Robert W. Baird lifted their target price on Twist Bioscience from $18.00 to $27.00 in a research report on Monday, August 7th. Berenberg Bank assumed coverage on Twist Bioscience in a research note on Wednesday, September 27th. They issued a “buy” rating and a $27.00 price target for the company. Finally, Barclays lifted their target price on Twist Bioscience from $20.00 to $26.00 and gave the stock an “overweight” rating in a research note on Monday, August 7th. Two equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Twist Bioscience presently has an average rating of “Moderate Buy” and an average target price of $28.43.

Hedge Funds Weigh In On Twist Bioscience

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Captrust Financial Advisors raised its holdings in shares of Twist Bioscience by 101.3% during the 2nd quarter. Captrust Financial Advisors now owns 759 shares of the company’s stock worth $27,000 after buying an additional 382 shares in the last quarter. US Bancorp DE grew its position in Twist Bioscience by 257.1% during the 2nd quarter. US Bancorp DE now owns 2,050 shares of the company’s stock worth $42,000 after acquiring an additional 1,476 shares during the last quarter. Canada Pension Plan Investment Board grew its position in Twist Bioscience by 155.6% during the 1st quarter. Canada Pension Plan Investment Board now owns 1,066 shares of the company’s stock worth $52,000 after acquiring an additional 649 shares during the last quarter. Lazard Asset Management LLC grew its position in Twist Bioscience by 73.4% during the 1st quarter. Lazard Asset Management LLC now owns 1,597 shares of the company’s stock worth $78,000 after acquiring an additional 676 shares during the last quarter. Finally, Amundi grew its position in Twist Bioscience by 30.5% during the 4th quarter. Amundi now owns 3,550 shares of the company’s stock worth $95,000 after acquiring an additional 830 shares during the last quarter.

About Twist Bioscience

Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium.